<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00251888</url>
  </required_header>
  <id_info>
    <org_study_id>CACIS</org_study_id>
    <nct_id>NCT00251888</nct_id>
  </id_info>
  <brief_title>CAmpto-CISplatine Plus Radiotherapy in Advanced Cervix Cancer : Search of Tolerated Maximum Dose of Campto</brief_title>
  <official_title>Etude de Recherche de Dose de l'Association Irinotecan (Campto(R)) - Cisplatine (Cisplatyl(R)) Avec la radiothérapie Pelvienne Dans Les Cancers avancés du Col de l'utérus.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ARCAGY/ GINECO GROUP</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ARCAGY/ GINECO GROUP</source>
  <brief_summary>
    <textblock>
      Search of maximum tolerated irinotecan dose in association with cisplatin and pelvic
      radiotherapy in patients with an advanced cervix cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine the maximum and the recommended tolerated dose of irinotecan with increasing
      doses associated with weekly cisplatin and combinated with pelvic radiotherapy in patients
      with an advanced cervix cancer, IIB-IVA FIGO stage.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2002</start_date>
  <completion_date type="Actual">November 2005</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the maximum tolerated dose of irinotecan associated with cisplatin and combinated with pelvic radiotherapy in patients with an advanced cervix cancer</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate :</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the global response rate judged on standard clinical criteria, echography, tomodensiometry, and MRI. The histologic response rate will be appreciated in patients who had a second surgery after pelvic radiochemotherapy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>local and general relapse frequency</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>global survival</measure>
  </secondary_outcome>
  <enrollment>15</enrollment>
  <condition>Cervix Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>campto (irinotecan)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin (cisplatyl)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven primitive epidermoid or andenocarcinoma Cervix

          -  FIGO stage IIB (obviously parameter attack), III or IVA

          -  No previous chemotherapy nor radiotherapy

          -  Patient for whom a radiochemotherapy is envisaged as first intention treatmentof her
             cervix carcinoma

          -  PS ECOG &lt; 2

          -  Life expectancy &gt; 12 weeks

          -  Written consent given

        Exclusion Criteria:

          -  Other malignant cervix tumor histology

          -  Visceral remotly metastasis

          -  Other malignant tumor since 5 years, except spino or baso-cellular treaten and cured
             cancer

          -  Anormal labs values

          -  Peripheric neuropathy CTC &gt; 2

          -  Auditory loss &gt; 2

          -  Cardiopathy

          -  Inflammatory digestive pathology

          -  Evolutive infection

          -  Other experimental concommitant treatment

          -  Lacting or pregnant women
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe Hennequin, Physician</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital St Louis, Paris, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nadine Dohollou, physician</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Bordeaux Nord, Bordeaux, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CRLC Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Claudius Régaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2005</study_first_submitted>
  <study_first_submitted_qc>November 10, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2005</study_first_posted>
  <last_update_submitted>January 24, 2017</last_update_submitted>
  <last_update_submitted_qc>January 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2017</last_update_posted>
  <keyword>cervix cancer</keyword>
  <keyword>advanced cervix cancer</keyword>
  <keyword>radiochemotherapy</keyword>
  <keyword>pelvic radiotherapy</keyword>
  <keyword>campto</keyword>
  <keyword>cisplatin</keyword>
  <keyword>irinotecan</keyword>
  <keyword>cisplatyl</keyword>
  <keyword>maximum dose search</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

